Research programme: neuroprotective agents - AdvanCell/DiverDrugsAlternative Names: DD 01012; DD 612
Latest Information Update: 29 Aug 2006
At a glance
- Originator AdvanCell; DiverDrugs
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued CNS trauma
Most Recent Events
- 29 Aug 2006 Discontinued - Preclinical for CNS trauma in Spain (unspecified route)
- 22 Feb 2002 Preclinical development for CNS trauma in Spain (Unknown route)